RxDoctor Payments Data

Hani Salha, MD

Cardiovascular Disease · Wyomissing, PANPI 1952391310

Payments from drug & device makers

$4,180in general payments, 2019–2025

Across 170 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Amarin Pharma, Inc.$393
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$376
  • Novartis$335
  • Pfizer$272
  • AstraZeneca$271
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,174100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,180 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$207,289
Medicare patients
959
Services billed
2,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban394$491,971
EntrestoSacubitril/Valsartan144$180,888
XareltoRivaroxaban119$139,112
Repatha SyringeEvolocumab54$55,010
FarxigaDapagliflozin Propanediol26$33,149
Repatha SureclickEvolocumab28$30,311
MultaqDronedarone Hcl22$29,246
VascepaIcosapent Ethyl33$16,200
Bisoprolol Fumarate425$14,874
Amiodarone Hcl169$10,120
Atorvastatin Calcium872$9,577
BrilintaTicagrelor12$9,347
JardianceEmpagliflozin11$6,835
Praluent PenAlirocumab11$6,652
Ezetimibe216$6,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$272$491,971394 claims
NovartisEntresto$335$180,888144 claims
Johnson & JohnsonXarelto$244$139,112119 claims
AstraZenecaFarxiga, Brilinta$271$42,49638 claims
Boehringer IngelheimJardiance$37$6,83511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →